XML 44 R32.htm IDEA: XBRL DOCUMENT v3.25.1

Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Information

Schedule of financial data for reportable segments

The following table presents certain financial data for the Company’s reportable segments for the three months ended March 31, 2025 and 2024 (in thousands):

​	​	​	​	​	​	​
​	​	​	March 31,
​	​	​	2025	​	​	2024
Revenue	​	$	10,000	​	$	-
Less:	​	​	​	​	​	​
Direct research and development expenses:1	​	​	​	​	​	​
Obexelimab	​	​	23,491	​	​	12,295
Other programs (ZB002 & ZB004)	​	​	203	​	​	894
Partnered regional programs (ZB001 & ZB005)	​	​	99	​	​	1,588
Unallocated research and development2	​	​	9,541	​	​	7,457
General and administrative3	​	​	8,610	​	​	4,397
Stock-based compensation	​	​	5,386	​	​	947
Other segment items4	​	​	(3,757)	​	​	222
Segment net loss	​	$	(33,573)	​	$	(27,800)

​

¹ Direct research and development expenses primarily consist of direct costs incurred to specific program research and development activities, including costs to conduct clinical trials and to manufacture clinical drug supply.

² Unallocated research and development expenses primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as personnel costs for employees involved in research and development activities, excluding stock-based compensation, as well as contract services not allocated to specific programs.

³ General and administrative expenses primarily consist of professional fees, depreciation expense, facilities expenses as well as all other personnel costs, excluding stock-based compensation.

⁴ Other segment items consist of other income (expense), net and income tax benefit (provision). Other income (expense), net consists of interest income and realized and unrealized gains and losses on foreign currency transactions.

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration